I Predicted Oracle Would Be the Hottest "Ten Titans" Stock to Buy in 2026, But the Growth Stock Is Already Down 27% This Year. Is Oracle Still a Buy?

Oracle shares have plunged (down ~52% from their all-time high and ~19.5% YTD) amid a broader software-sector sell-off and rising investor skepticism about AI-related backlog. Management projects OCI revenue to jump from roughly $10bn in FY2025 to $144bn by FY2030, supported by a reported RPO that rose 359% to $523bn, but roughly $300bn of that RPO is reportedly tied to OpenAI — prompting funding and counterparty concerns. The company is no longer free-cash-flow positive and is using debt to finance data-center expansion; valuation sits around 26.8x trailing and 19.4x forward earnings, leaving the investment case contingent on Oracle’s core software cash generation, OpenAI fulfillment, or reallocation of capacity to other customers.

Analysis

Market structure: The sell-off disproportionately penalizes software/cloud vendors with concentrated AI-capex counterparties (Oracle ORCL, ServiceNow NOW) while benefitting AI-infrastructure and semiconductor suppliers (NVIDIA NVDA, Broadcom AVGO). Oracle’s $523bn RPO with ~$300bn tied to OpenAI creates single-counterparty risk; if utilization falls 20–50% over 12–24 months, OCI pricing and utilization could compress margins by hundreds of basis points. Cross-asset: expect widening credit spreads for levered cloud builders, rising equity vols (esp. ORCL/NOW/MSFT), modest USD safe-haven flow, and down-tick in cyclical energy demand if cloud capex is deferred.

Risk assessment: Tail risks include OpenAI funding failure (>=50% RPO write-down), regulatory constraints on AI partnerships, or OCI execution failures; any of these could knock ORCL EPS down >10% over 12 months. Near-term (days–weeks) we should expect flow-driven de-risking around earnings; medium term (3–12 months) depends on OpenAI fundraising and GPU supply; long term (2–5 years) outcome tracks AI adoption and Oracle’s ability to redeploy capacity. Hidden dependencies: RPO is not cash — conversion timings and contract termination clauses matter and can cascade to covenant/credit metrics.

Trade implications: Construct small, tactical positions: bias long NVDA and AVGO (AI infra) and short concentrated cloud/software names (ORCL, NOW) via puts or equity. Prefer dollar‑neutral pair trades (long NVDA / short ORCL) to isolate AI infra vs software exposure, 90‑day horizon, rebalance monthly. Use options to express skew: buy 3–6 month ORCL puts (10–20% OTM) and buy 3–6 month NVDA call spreads to limit capital and exploit volatility.

Contrarian angles: Consensus underestimates Oracle’s legacy software cash flow — if OpenAI funds and utilization returns, ORCL could re-rate quickly; conversely, overcapacity could force price competition and accelerate consolidation (M&A). Historical parallel: 2019–2020 cloud capex cycles saw sharp mid‑cycle corrections followed by concentrated winner takeaways; mispricings exist where RPO fears are binary but conversion risk is gradual, creating asymmetric option-like payoffs.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in NVDA within 2 weeks (or equivalent 3–6 month call-spread) targeting +30–35% in 3–6 months; set a tactical stop-loss at -15% to control drawdown given elevated vol.
• Initiate a 1–1.5% portfolio short stance on ORCL using 3–6 month 10–20% OTM puts (preferred) or short equity with a stop if ORCL rallies >15% from entry; thesis: >$200bn effective RPO concentration to OpenAI creates >10% EPS downside risk if funding weakens.
• Implement a dollar‑neutral pair trade: long NVDA / short ORCL (1:1 notional) for a 90‑day trade, rebalance monthly and exit on next Oracle earnings or a public OpenAI financing update to capture relative performance vs sector flows.
• Trim high-multiple pure SaaS exposure (e.g., reduce NOW/CRM exposure by ~25%) within 30 days and redeploy proceeds into AVGO or AMZN (AWS) sized 1–3% each with 6–12 month holds to favor infrastructure over concentrated software risk.
• Allocate a 0.5% portfolio contrarian asymmetric bet: buy a 12‑18 month ORCL call spread ~30% OTM (limited premium) to capture a rapid re-rating if OpenAI funding or large renewals materialize.